диссертации / 29
.pdf100.Шкребец Г.В. Варианты клинического течения и эффективность лечения периферического увеита у детей и подростков: Автореф. канд. мед. наук… Москва, 2009 26c.
101.Штейн Л.Б. Опыт прогнозирования в медицине с помощью ЭВМ. Л., издательство ЛГУ, 1987. 146 c.
102.Шураева Н. Ю. Молекулярно-клеточные механизмы стимули-
103.рующего действия низкоинтенсивного лазерного (когерентного) и не-
104.когерентного (светодиодного) излучений на процесс заживления ран: Автореф. дис. ... канд. мед. наук, Москва, 2005 – 22с.
105.Якименко И.Л., Сидорик Е.П. Регулирующее действие низкоинтенсивного лазерного излучения на состояние антиоксидантной системы организма //Укр. биохим. журнал. – 2001. –
Т. 73, N 1. – С. 16-23.
106.Abelson М.В., Butrus S. Corticosteroids in ophthalmic practice // Principles and Practice of Ophthalmology: Basic Sciences / WB Saunders, 1994. P. 1013-1022.
107.Baggiolini M. Chemokines and leukocyte traffic // Nature. 1998. Vol. 392.
P. 565 – 568.
108.Baggiolini M., Dewald B., Moser B. Interleukin-8 and related chemotactic cytokines – CXC and CC chemokines // Adv. Immunol. 1994. Vol. 55(2). P. 91-104.
109.Becker M.D., Adamus G., Davey M.D., Rosenbaum I.T. The role of T-cells in autoimmune uveitis// Ocul. Immunol. and Inflam. – 2000 Vol.8, №2. – Р.93-100.
131
110.Beyer A., Rosche B., Pleyer U., Wandinger K.P. Stellenwert der Uveitis im Rahmen demyelinisierender Erkrankungen des Zentralnervensystems // Springer Medizin Verlag, Berlin, 2007.
111.Chan C., Li Q. Immunopatology of uveitis//»Еye» an international journal of ophthalmology.- 1997Volume 11 № 2. P. 91-95.
112.Chan C., Mochizuki M., Palestine J. Kinetics of T–lymphocyte subsets in the eyes of Levis rats with experimental autoimmune uveitis. // Cell Immunol.–1985. – Vol. 96. – P.430-434.
113.Chang J.H., McCluskey P., Wakefield D. Acute anterior uveitis and HLAB27 // Survey of ophthalmology. — 2005. — Vol. 50(4). — P. 364-388.
114.Cohen S., Bigazzi P., Yoshida T. Similarities of T cell function in
cell_mediated immunity and antibody production // Cell. Immunol. — 1974.
— № 12. — P. 150-159.
115.Creemers MC, Jacobs JW van Agtmael MA, van de Laar MA, van der Poll T, Tak PP, Bijlsma JW TNF-blocking drugs and infection; recommendations for daily practice // Ned Tijdschr Geneeskd. 2007. - Vol.
151(10). - P. 588-593.
116.Cunnusamy K., Niederkorn J. Y. IFN-γ Blocks CD4+CD25+ Tregs and Abolishes Immune Privilege of Minor Histocompatibility Mismatched Corneal Allografts// American Journal of Transplantation. 2013.-Vol. 13(12). 3076-3084.
117.De Smet MD News on therapies for uveitis. //J Fr Ophth 2005; 28 (5): Р. 556.
118.De Vos A.F., Klaren V.N., Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat // Invest. Ophthalmol. Vis. Sci. — 1994. — Vol. 35(11). — P. 3873-3883.
132
119.Dumonde D.C., Kasp-Grochowska E., Graham E., Sanders M.D., Faure J.P., de Kozak Y., van Tuyen V. Anti-retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis London. Lancet// 1982. - Vol 2(8302). Р787-792.
120.Elsching A. Studien zur sympathischen ophthalmic. Die antigene wirkung des augenpigmentes. Albrecht von Graefes Arch. Ophthalmol.–1910.– №
76.– P. 509-546.
121.Ferguson T.A., Griffith T.S. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response // Chem. Immunol. Allergy. 2007. - № 92. P. 140-154.
122.Forrester J.V. Endogenous posterior uveitis // Br. J. Ophthalmol. 1990. Vol. 74(10). P. 620-623.
123.Forrester J.V., Shafiee A., Schröder S., Knott R., McIntosh L. The role of growth factors in proliferative diabetic retinopathy// Eye – 1993. -№ 7. – P. 276-287.
124.Foster C.S. Vitale A.T. Diagnosis and treatment of uveitis//Philadelphia.: W.B. Saunders Company, 2nd edition, 2002. 900p.
125.Foster C. S., Fiorelli V.M., Bhat P.S. Nonsteroidal anti-inflammatory therapy and reccurent acute anterior uveitis//. Ocul Immunol Inflamm. 2010. Vol. 18(2). P. 116-120.
126.Fujikawa L.S., Palestine A.G., Schwartz L.K. and Nussenblatt R.B. Ocular involvement in the acquired immunodeficiency syndrome//Biomedical Foundations of Ophthalmology , Thomas D. Duane editor, Harper & Row Publishers, Philadelphia, Chapter 36, 1986. P.31-35.
133
127.Gery I., Mochizuki M., Nussenblatt RB. Retinal specific antigens and immunopathogenic processes they provoke. // Oxford, Pergamon Press, 1986. № 5.– P. 75-109.
128.Gilbert R.E., Stanford M.R 5 Treating ocular toxoplasmosis: current evidence Incidence of acute symptomatic toxoplasma retinochoroiditis in south// Mem Inst Oswaldo Cruz. 2009. V. 104(2) P. 312-315.
129.Graham E.M., Stanford M.R., Sanders M.D. et all, Diagnostic value of ophthalmological features.// Br J Ophthalmol. - 1989. – №73. P. 714721.
130.Green, D.R. and Ware C.F. Fas-ligand: privilege and peril// Proc Natl Acad Sci USA. 1997. Vol 94 (12). P 5986-5990.
131.Hong S., Van Kaer L. Immune Privilege: Keeping an Eye on Natural Killer T Cells// The Journal of Experimental Medicine - 1999. – Vol 190 (9) - P. 1197—1200.
132.Janeway C. A.Jr., Travers P., Walport M., Shlomchik M.J. ImmunoBiology, the immune system in health and disease 6th Edition. - Garland Science, 2005. - 56p.
133.Klok A., Luyendijb L., Zaal M., Rothova A., e.a. Elevated serum IL–8 levels are associated with disease activity in intermediate uveitis. // Br. J. Ophthalmology, 1998. – № 8. – P. 871 – 874.
134.Lacomba M.S., Martin C.M., Chamond R.R. et al. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis // Arch. Ophthalmol. — 2003. — № 135. — P. 676 - 680.
135.Lim L., Suhler EB., Smith JR. Biologic therapies of inflammatory eye disease. // Clin Exp Ophthalmol. – 2006. Vol. 34 (4) 365-374.
134
136.Lundvall A., Zetterstrom C. Cataract extraction and intraocular lens implantation in children with uveitis / A. Lundvall, C. // Br. J. Ophthalmol. 2000. № 84. P. 791-793.
137.Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int. J. Hematol. – 2000. № 72. P. 391398.
138.Nussenblatt R.B., Palestine A.G. Uveitis. Fundamental and Clinical Practice. // Year book medical publishers, inc.–Chicago, London. – 1989. – 443 p.
139.Ohshiro T., Calderhead R.G. Low level laser therapy: a Practical Introduction. – Chichester – New York. – “John Willy and Sons”. – 1988. – 141 p.
140.Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP The pathophysiologic roles of interleukin-6 in human disease //An edited summary of a Clinical Staff Conference at the National Institutes of Health, Bethesda, MD, USA, 1998. - 128(2). Р. 127-137.
141.Pederson J.E., Kenyon K.R., Grean W.R. Pathology of pars planitis// Am J Ophtalmol.1978, 86(6) P.762-774.
142.Pedrotti L., Pedrotti F., Bausch W. Optik Fur Ingenieurie: Grundlagen. Publisher: Springer, 2007. P. 848.
143.Prasad S.A., Gregerson D.S. Antigen Presentation in uveitis //Part 2 Cambridge ophtalmological symposium Royal College of ophtalmologists.- P176-182.
144.Prendergast R.A., Iliff CE, Coskuncan NM, Caspi RR, Sartani G, Tarrant TK, Lutty GA, McLeod DS. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis // Invest. Ophthalmol. Vis. Sci. 1998. Vol. 12(3). P. 145-155.
135
145.Prihovra E., Havlrikovra M., Mehalovra K. Acute anterior uveitis, systemic diseases and HLA-B27 // Cesk. Slov. Oftalmol. 1997. -Vol. 53(2). - P. 80-87.
146.Rampart M., Van Damme J., Zonnekeyn L., e.a. Cranylocyte chemotactic protein/ interleukin 8 induces plasma leakage and neutrophil accumulation in rabbit skin // Am.J.Phatol. 1989. Vol. 135(1). P. 21 – 25.
147.Scott M., Whitcup M.D., Robert B., Nussenblatt M. Immunologic Mechanisms of Uveitis // Ocular immunology and inflammation. 1993. V. 1(3). – P. 255-262.
148.Solomon A. S., Amir A., Lavie V. Neon helium the laser inspiration reduces anoxia - the caused degeneration of the rabbit retinal cells of a nerve ganglion //Effects of the laser of low energy on biological systems: SPIE′S
1883 editions of Hearing, Los Angeles, USA. – 1993. – P. 130-136.
149.Sonoda K.H. Association of ocular inflammation and innate immune response // Nippon Ganka Gakkai Zasshi. 2008. Vol. 112(3). P. 279297.
150.Tuner J., Hode L. Laser therapy in dentistry and medicine. – Stockholm, Sweden: Prima Books, 1996. – 236 p.
151.Valentincic N.V., de Groot-Mijnes J.D., Kraut A., Korosec P., Hawlina M., Rothova A. Intraocular and serum cytokine profiles in patients with intermediate uveitis// Molecular Vision ;Utrecht, 2011 № 17 P. 20032010.
152.Van Damme J, Van Beeumen J, Opdennakker G NH2-terminal sequencecharacterized human monokine possessing neutrophil chemotactic, skinreactive, and granulocytosis – promoting activity // J.Exp.Med. 1988. 167(4). P. 1364 – 1376.
136
153.Wacker W.B., Donoso L.A., Kalsow C.M., et al.. Experimental allergic uveitis. Isolation, characterization and localization of a soluble uveitopathogenic antigen from bovine retina. // J. Immunol.– 1977.–Vol. 119.– P. 1949-1958.
154.Whitcup S.M. The initiating stimuli for uveitis// Еye. - 1997. №11 P. 167-170.
155.Whitcup SM1, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease//Am J Ophthalmol. 1994. 118(1) P. 39-45.
156.Willbanks G. A., Rootman D. S., Jay V. et al. Experimental autoimmune uveitis in HLA-B27 transgenic mice // Hum. Immunol. — 1997. — Vol. 53
157.( 2). — P. 188—194.
158.Woods A.C. Endogenous Inflammation of the Uveal Tract//Baltimore: Lippincott Williams&Wilkins, 1961. – P. 76-79.
137